Actualités First Trust Cloud Computing Ucits Etf - SKYE | Actions Euronext

Newbridge Announces Nanotechnology Index (NYSEArca: NNIX) Quarterly Rebalance and Inside Nanotechnology 2Q07 Research Report Rel

FORT LAUDERDALE, Fla., May 21 /PRNewswire/ -- Newbridge Securities Corporation today announced the quarterly rebalancing and reconstitution of...

SkyePharma Reports Positive Phase III and EU Filing for Lodotra(TM)

LONDON, Oct. 4 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) today announces positive results of a Phase III clinical...

SkyePharma to Reorganise Certain Management Functions

LONDON, Sept. 22 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) announces today that as part of the Company's ongoing...

SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in Europe

Euro 15 million upfront and Euro 70 million in milestones Double Digit Royalties LONDON, Sept. 6 /PRNewswire-FirstCall/ -- SkyePharma PLC...

SkyePharma to Announce 2006 Interim Results on 28 September

LONDON, Sept. 5 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKPLSE:Nasdaq:LSE:SKYE) announces today that the Company will issue its interim...

SkyePharma PLC - Annual General Meeting Statement

LONDON, June 28 /PRNewswire-FirstCall/ -- The Annual General Meeting of SkyePharma plc (LSE:SKPLSE:Nasdaq:LSE:SKYE) was held in London today...

SkyePharma's Chief Operating Officer Appointed to Board

LONDON, May 17 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) announces the appointment of Dr Ken Cunningham, Chief Operating...

SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform(TM)

LONDON, May 8 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) and Kos Pharmaceuticals, Inc. (Nasdaq: KOSP, "Kos") will host a...

SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United States

LONDON, May 8 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) announces today that it has entered into an agreement with Kos...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

First Trust Cloud Computing Ucits Etf (SKYE)

Votre Hub pour des idées et discussions en direct en temps réel

SKYE Actualités

Newbridge Announces Nanotechnology Index (NYSEArca: NNIX) Quarterly Rebalance and Inside Nanotechnology 2Q07 Research Report Rel

SkyePharma Reports Positive Phase III and EU Filing for Lodotra(TM)

SkyePharma to Reorganise Certain Management Functions

SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in Europe

SkyePharma to Announce 2006 Interim Results on 28 September

SkyePharma PLC - Annual General Meeting Statement

SkyePharma's Chief Operating Officer Appointed to Board

SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform(TM)

SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United States

SkyePharma Announces First European Approval of DepoDur(TM)

SkyePharma PLC - Preliminary Results Announcement for the Year Ended 31 December 2005

SkyePharma's Chief Executive Appointed to Board

SkyePharma to Announce 2005 Full Year Results on 19 April and to Hold Business Review Meeting on 21 June

SkyePharma PLC Clarification of Financial Position

SkyePharma Initial Response to Allegations Made by North Atlantic Value Group

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

First Trust Cloud Computing Ucits Etf (SKYE) Actualités

First Trust Cloud Computing Ucits Etf (SKYE)

Votre Hub pour des idées et discussions en direct en temps réel

SKYE Actualités

Newbridge Announces Nanotechnology Index (NYSEArca: NNIX) Quarterly Rebalance and Inside Nanotechnology 2Q07 Research Report Rel

SkyePharma Reports Positive Phase III and EU Filing for Lodotra(TM)

SkyePharma to Reorganise Certain Management Functions

SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in Europe

SkyePharma to Announce 2006 Interim Results on 28 September

SkyePharma PLC - Annual General Meeting Statement

SkyePharma's Chief Operating Officer Appointed to Board

SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform(TM)

SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United States

SkyePharma Announces First European Approval of DepoDur(TM)

SkyePharma PLC - Preliminary Results Announcement for the Year Ended 31 December 2005

SkyePharma's Chief Executive Appointed to Board

SkyePharma to Announce 2005 Full Year Results on 19 April and to Hold Business Review Meeting on 21 June

SkyePharma PLC Clarification of Financial Position

SkyePharma Initial Response to Allegations Made by North Atlantic Value Group

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités